# The Efficacy and Safety of Short-course Radiation Combined With Adebrelimab and CAPEOX Neo-adjuvant Therapy for Organ-retention in Patients With MSS/pMMR Ultra Low Rectal Adenocarcinoma

> **NCT06266832** · PHASE2 · RECRUITING · sponsor: **Sir Run Run Shaw Hospital** · enrollment: 30 (estimated)

## Conditions studied

- Rectal Adenocarcinoma

## Interventions

- **DRUG:** Adebrelimab
- **DRUG:** Oxaliplatin
- **DRUG:** Capecitabine
- **RADIATION:** Short-course Radiation
- **PROCEDURE:** Biopsy

## Key facts

- **NCT ID:** NCT06266832
- **Lead sponsor:** Sir Run Run Shaw Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-01-01
- **Primary completion:** 2025-01-01
- **Final completion:** 2027-12-31
- **Target enrollment:** 30 (ESTIMATED)
- **Last updated:** 2024-02-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06266832

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06266832, "The Efficacy and Safety of Short-course Radiation Combined With Adebrelimab and CAPEOX Neo-adjuvant Therapy for Organ-retention in Patients With MSS/pMMR Ultra Low Rectal Adenocarcinoma". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT06266832. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*